

Cirrhosis in over 16s: assessment and management (update)

Review questions

NICE guideline <number>

List of review questions

May 2023

*Commissioned by the National Institute
for Health and Care Excellence*

Disclaimer

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and, where appropriate, their carer or guardian.

Local commissioners and providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the [Welsh Government](#), [Scottish Government](#), and [Northern Ireland Executive](#). All NICE guidance is subject to regular review and may be updated or withdrawn.

Copyright

© NICE [2023]. All rights reserved. Subject to [Notice of rights](#).

Contents

1	Review questions	5
----------	-------------------------------	----------

1 Review questions

Review Question 1	What is the clinical and cost-effectiveness of non-selective beta-blockers (NSBBs), endoscopic variceal band ligation (EVL) or NSBBs plus EVL compared to each other for the primary prevention of bleeding in people with medium to large oesophageal varices due to cirrhosis?
Review Question 2	What is the clinical and cost-effectiveness of antibiotics compared with placebo for the primary prevention of spontaneous bacterial peritonitis (SBP) in people with cirrhosis and ascites?
Review Question 3	What is the clinical and cost effectiveness of non-selective beta-blockers (NSBBs) for the primary prevention of decompensation in people with compensated cirrhosis?